Details

Autor(en) / Beteiligte

• Hu, Shimin
• Xu-Monette, Zijun Y.
• Tzankov, Alexander
• Green, Tina
• Wu, Lin
• Balasubramanyam, Aarthi
• Liu, Wei-min
• Visco, Carlo
• Li, Yong
• Miranda, Roberto N.
• Montes-Moreno, Santiago
• Dybkaer, Karen
• Chiu, April
• Orazi, Attilio
• Zu, Youli
• Bhagat, Govind
• Richards, Kristy L.
• Hsi, Eric D.
• Choi, William W.L.
• Zhao, Xiaoying
• van Krieken, J. Han
• Huang, Qin
• Huh, Jooryung
• Ai, Weiyun
• Ponzoni, Maurilio
• Ferreri, Andrés J.M.
• Zhou, Fan
• Slack, Graham W.
• Gascoyne, Randy D.
• Tu, Meifeng
• Variakojis, Daina
• Chen, Weina
• Go, Ronald S.
• Piris, Miguel A.
• Møller, Michael B.
• Medeiros, L. Jeffrey
• Young, Ken H.

Titel

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Ist Teil von

• Blood, 2013-05, Vol.121 (20), p.4021-4031

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein coexpression occurred significantly more commonly in the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2 coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression. DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP. •DLBCL patients with MYC/BCL2 coexpression demonstrate inferior prognosis and high-risk gene expression signatures.